Theravance Biopharma (NASDAQ:TBPH) Trading 5.7% Higher on Analyst Upgrade

Theravance Biopharma, Inc. (NASDAQ:TBPHGet Free Report)’s share price traded up 5.7% on Friday after BTIG Research raised their price target on the stock from $24.00 to $25.00. BTIG Research currently has a buy rating on the stock. Theravance Biopharma traded as high as $11.22 and last traded at $11.35. 77,972 shares traded hands during trading, a decline of 71% from the average session volume of 268,919 shares. The stock had previously closed at $10.73.

TBPH has been the topic of a number of other research reports. Wall Street Zen raised Theravance Biopharma from a “hold” rating to a “buy” rating in a report on Saturday, June 21st. Jones Trading raised shares of Theravance Biopharma to a “strong-buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, June 17th. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.60.

Check Out Our Latest Stock Analysis on Theravance Biopharma

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the firm’s stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its position in Theravance Biopharma by 3.8% in the 1st quarter. Rhumbline Advisers now owns 62,254 shares of the biopharmaceutical company’s stock worth $556,000 after purchasing an additional 2,293 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Theravance Biopharma by 121,993.7% during the 1st quarter. Acadian Asset Management LLC now owns 174,594 shares of the biopharmaceutical company’s stock valued at $1,554,000 after buying an additional 174,451 shares in the last quarter. Jane Street Group LLC lifted its position in shares of Theravance Biopharma by 169.2% during the 1st quarter. Jane Street Group LLC now owns 140,884 shares of the biopharmaceutical company’s stock valued at $1,258,000 after buying an additional 88,540 shares in the last quarter. Park West Asset Management LLC lifted its holdings in Theravance Biopharma by 0.6% during the first quarter. Park West Asset Management LLC now owns 1,804,244 shares of the biopharmaceutical company’s stock valued at $16,112,000 after purchasing an additional 11,256 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in Theravance Biopharma during the first quarter valued at $101,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Price Performance

The firm has a market capitalization of $561 million, a PE ratio of -9.51 and a beta of -0.09. The company’s fifty day simple moving average is $10.00 and its 200-day simple moving average is $9.51.

Theravance Biopharma (NASDAQ:TBPHGet Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. The firm had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $28.08 million. Analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

About Theravance Biopharma

(Get Free Report)

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

See Also

Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.